Are Australians Able to Access New Medicines on the Pharmaceutical Benefits Scheme in a More or Less Timely Manner? An Analysis of Pharmaceutical Benefits Advisory Committee Recommendations, 1999–2003
Trends in the Measurement of Health Utilities in Published Cost-Utility Analyses
An Economic Evaluation of Two Ototopical Treatments for Acute Otitis Media in Tympanostomy Tube Patients
Estimating the Cost-Effectiveness of Fluticasone Propionate for Treating Chronic Obstructive Pulmonary Disease in the Presence of Missing Data
Managing Meningococcal Disease in the United States
Probabilistic Analysis and Computationally Expensive Models
Indirect Costs and Cost-Effectiveness Analysis
Comparing the EQ-5D and the SF-6D Descriptive Systems to Assess Their Ceiling Effects in the US General Population
Fraction of Nursing Home Admissions Attributable to Urinary Incontinence
Applying the Grid Computation in Long-Term Retrospective Health Insurance Data Analysis
Is Rosuvastatin Really a More Efficient Therapeutic Option than Atorvastatin?
Formulary Decision-Making Should Rely on the Best Available Evidence